A number of other equities analysts have also weighed in on AGLE. ValuEngine upgraded Aeglea Bio Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. HC Wainwright reiterated a buy rating and issued a $20.00 price target on shares of Aeglea Bio Therapeutics in a research report on Monday, June 3rd. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Aeglea Bio Therapeutics has a consensus rating of Buy and an average target price of $14.33.
NASDAQ:AGLE opened at $8.50 on Thursday. The company has a quick ratio of 8.44, a current ratio of 8.44 and a debt-to-equity ratio of 0.05. Aeglea Bio Therapeutics has a 1-year low of $5.99 and a 1-year high of $10.49. The firm has a market capitalization of $256.21 million, a price-to-earnings ratio of -3.99 and a beta of 1.09. The stock has a fifty day simple moving average of $8.06 and a 200 day simple moving average of $7.41.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter worth about $27,000. BNP Paribas Arbitrage SA acquired a new stake in Aeglea Bio Therapeutics during the 1st quarter worth about $32,000. Bank of Montreal Can boosted its position in Aeglea Bio Therapeutics by 116.5% during the 2nd quarter. Bank of Montreal Can now owns 6,749 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 3,631 shares during the period. Commonwealth Equity Services LLC acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter worth about $68,000. Finally, Susquehanna International Group LLP acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter worth about $83,000. Hedge funds and other institutional investors own 69.35% of the company’s stock.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
See Also: Diversification
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.